Drug Search Results
More Filters [+]

ICP-248

Alternative Names: ICP-248, ICP248, ICP 248
Latest Update: 2024-10-24
Latest Update Note: Clinical Trial Update

Product Description

ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor, which aims to treat non- Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and other malignant hematological tumors as a monotherapy or in combination with BTK inhibitors and other drugs. BCL2 is an important part of apoptotic pathway and is overexpressed in a variety of hematologic malignancies. ICP-248 has anti-tumor effects by activating the endogenous mitochondrial apoptosis pathway that causes rapid cancer cell apoptosis. (Sourced from: https://www.businesswire.com/news/home/20220912005570/en/InnoCare-Announces-Approval-of-Clinical-Trial-of-BCL2-Inhibitor-ICP-248-in-China)

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innocare Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ICP-248

Countries in Clinic: China

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

Phase 1: Acute Myeloid Leukemia|Oncology Hematological Unspecified|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ICP-CL-01203

P3

Recruiting

Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2030-11-25

ICP-CL-01202

P1

Not yet recruiting

Oncology Unspecified

2027-06-25

R/R AML

P1

Not yet recruiting

Acute Myeloid Leukemia

2027-06-01

ICP-CL-01201

P1

Recruiting

Oncology Hematological Unspecified|Oncology Unspecified

2024-08-30

21%

Recent News Events